Laguna Pharmaceuticals, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2006-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.chanrx.com
Safety and Efficacy of Vanoxerine for the Conversion of Subjects With Recent Onset Atrial Fibrillation or Flutter to Normal Sinus Rhythm
Phase 3
Terminated
- Conditions
- Atrial Fibrillation or Flutter
- Interventions
- Drug: Placebo
- First Posted Date
- 2015-05-27
- Last Posted Date
- 2016-10-17
- Lead Sponsor
- Laguna Pharmaceuticals, Inc.
- Target Recruit Count
- 41
- Registration Number
- NCT02454283
Safety and Efficacy of Vanoxerine for Conversion of Atrial Fibrillation or Flutter to Normal Sinus Rhythm
Phase 2
Completed
- Conditions
- Symptomatic Atrial FibrillationAtrial Flutter
- Interventions
- Drug: Placebo
- First Posted Date
- 2012-09-24
- Last Posted Date
- 2015-12-22
- Lead Sponsor
- Laguna Pharmaceuticals, Inc.
- Target Recruit Count
- 104
- Registration Number
- NCT01691313
© Copyright 2025. All Rights Reserved by MedPath